This is a collaborative study between investigators from the University of Pittsburgh (Pitt) and Washington University (WashU) to delineate the genetic architecture of Alzheimer’s disease (AD) and AD-related proteinopathies. The participants are from a number of genetic studies being carried out on AD and AD-related dementias and non-AD subjects from 1) the Pitt-ADRC and ancillary studies and 2) Knight-ADRC Memory and Aging Project (MAP) study. The study samples are comprised of approximately 90% whites, 10% blacks, and 50% females with a mean age of 77.7 years.

Carlos Cruchaga
Washington University

Ilyas Kamboh
University of Pittsburgh

Genetic Architecture of Alzheimer’s Disease Proteinopathies – R01 AG064877

Acknowledgment statement for any data distributed by NIAGADS:

Data for this study were prepared, archived, and distributed by the National Institute on Aging Alzheimer's Disease Data Storage Site (NIAGADS) at the University of Pennsylvania (U24-AG041689), funded by the National Institute on Aging.

For investigators using Genetic Architecture of Alzheimer’s disease and Related Proteinopathies data:

This work was made possible by the support from the National Institutes of Health grants:

Pitt: AG064877, AG030653, AG041718, P30-AG066468, U01 AT000162, AG023651, AG052521, AG025516, UF1 AG051197, P01 AG025204, RF1 AG052525, AG052446.

WashU: R01AG044546, P01AG003991, RF1AG053303, R01AG058501, U01AG058922, RF1AG058501 and R01AG057777). The recruitment and clinical characterization of research participants at Washington University were supported by NIH P50 AG05681, P01 AG03991, and P01 AG026276. This work was supported by access to equipment made possible by the Hope Center for Neurological Disorders, and the Departments of Neurology and Psychiatry at Washington University School of Medicine.

We thank the contributors who collected samples used in this study, as well as patients and their families, whose help and participation made this work possible. This work was supported by access to equipment made possible by the Hope Center for Neurological Disorders, and the Departments of Neurology and Psychiatry at Washington University School of Medicine.

Ali, Muhammad et al. Leveraging large multi-center cohorts of Alzheimer disease endophenotypes to understand the role of Klotho heterozygosity on disease risk. PloS one vol. 17,5 e0267298. 26 May. 2022, doi:10.1371/journal.pone.0267298. PubMed Link

Yang, et al. Genomic atlas of the proteome from brain, CSF and plasma prioritizes proteins implicated in neurological disorders. Nature Neuroscience. 2021. doi: 10.1038/s41593-021-00886-6. PubMed link

Olive, et al. Examination of the Effect of Rare Variants in TREM2, ABI3, and PLCG2 in LOAD Through Multiple Phenotypes. Journal of Alzheimer’s Disease. 2020. doi: 10.3233/JAD-200019. PubMed link